BTIG Research Issues Pessimistic Forecast for Xtant Medical (NYSEAMERICAN:XTNT) Stock Price

Xtant Medical (NYSEAMERICAN:XTNT) had its price objective reduced by analysts at BTIG Research from $1.50 to $1.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. BTIG Research’s target price would indicate a potential upside of 87.93% from the company’s previous close.

Separately, Craig Hallum restated a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, Xtant Medical currently has an average rating of “Buy” and a consensus target price of $1.00.

Xtant Medical Trading Down 4.6%

XTNT opened at $0.53 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. Xtant Medical has a fifty-two week low of $0.34 and a fifty-two week high of $0.95. The company’s 50 day moving average price is $0.59 and its two-hundred day moving average price is $0.67. The firm has a market capitalization of $74.49 million, a price-to-earnings ratio of 17.74 and a beta of -0.16.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $32.36 million during the quarter, compared to the consensus estimate of $30.75 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Institutional Investors Weigh In On Xtant Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Xtant Medical during the second quarter valued at about $26,000. Tradition Wealth Management LLC bought a new stake in Xtant Medical in the 4th quarter valued at about $79,000. Wiregrass Investment Management LLC bought a new stake in Xtant Medical in the 4th quarter valued at about $81,000. Mink Brook Asset Management LLC raised its stake in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after buying an additional 60,997 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Xtant Medical during the 4th quarter worth approximately $220,000. 69.33% of the stock is owned by institutional investors.

Xtant Medical News Summary

Here are the key news stories impacting Xtant Medical this week:

• Positive Sentiment: Q4 / FY2025 beat — Xtant reported Q4 EPS roughly $0.03 (vs. negative street expectation) and full-year 2025 revenue of $133.9M, up 14% year‑over‑year; the company delivered positive net income, adjusted EBITDA and operating cash flow, supporting near-term fundamentals. Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Improved liquidity — cash on hand was $17.3M at year‑end plus an additional $10.5M received after year‑end from a divestiture, which reduces near-term financing pressure. Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Analyst stance still constructive — BTIG lowered its price target from $1.50 to $1.00 but maintained a “buy” rating, signaling confidence in upside versus the current share price despite more conservative near-term estimates. Benzinga
• Neutral Sentiment: Full earnings and call transcripts are available (useful for management commentary and Q&A details). Review the transcript for color on margin drivers and divestiture timing. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Weak 2026 outlook — management guided 2026 revenue to $95M–$99M and said Companion Spine divestiture plus the roll‑off of Q‑code license revenue will reduce next year’s top line materially versus 2025, which is the primary driver of the negative market reaction. Xtant outlines $95M-$99M 2026 revenue outlook
• Negative Sentiment: Market reaction — coverage notes the weak 2026 guide overshadowed the Q4 beat and shares moved lower on the outlook and revenue headwinds; watch upcoming quarterly cadence and any updated cadence for divestiture‑related revenue. Xtant Medical shares drop nearly 5%

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.